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Abstract 
Background: 
Long-term quality of life (QoL) after liver resection (LR) is becoming increasingly 
important, as improvements in operative methods and perioperative care diminished in 
morbidity and mortality. In this study, postoperative QoL after LR for benign or malignant 
tumors was evaluated. 
Methods: 
In this single center study, QoL was evaluated prospectively using the EORTC QLQ-C30 
and the liver-specific QLQ-LMC21 module preoperatively and 1, 3, 6 and 12 months after 
open or laparoscopic liver surgery. 
Results:  
Between 06/2007 and 01/2013 n=188 patients (malignant n=130, benign n=58) requiring 
major LR were included. Global health status was equally bad in both groups 
preoperatively and one month after LR. All patients showed an improvement in global 
health status at 3, 6 and 12 months post operation. Patients with benign tumors had better 
global health status than those with malignant tumors during the same periods (p<0.001, 
p = 0.002, p = 0.006, respectively). Patients with benign disease had better physical 
functioning scores at 3, 6 and 12 months (p=0.011, p=0.025, p=0.041) and lower fatigue 
score at 3, 6 and 12 month compared to patients with malignant disease (p=0.001, 
p=0.002, p=0.002).  
Conclusion: 
This study confirms overall good QoL in patients undergoing LR for benign or malignant 
tumors which improved after surgery. Benign diseases were associated with better short 
and long-term QoL scores after LR.  
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Introduction 
Advances in surgical technique, anesthesiology and perioperative care have resulted in a 
decrease in postoperative mortality and morbidity after major hepatic surgery in 
specialized liver units 1, 2. As a result, the indications for and the extent of liver resections 
(LR) are being expanded 3-5 with “patient-tailored” medicine and individualized resection 
strategies becoming increasingly important 6. Due to these developments, including 
advances in adjuvant therapies, survival following LR for colorectal metastases as well as 
hepatocellular carcinoma (HCC) and cholangiocarcinoma, have increased in the last 
decades 7-11. With reduced morbidity and increased post-hepatectomy survival, quality of 
life (QoL) becomes a leading issue and, particularly from a patient’s point of view, as 
important as disease-free or overall survival 12-14. 
The term “Quality of life” (QoL) is used more frequently and tries to capture aspects of 
patient care and therapeutic goals previously not taken into account. QoL is subjective, 
multidimensional and dynamic over time, continuously fluctuating as it responds to life 
events. It includes a variety of domains and parameters, including physical, functional, 
social, and emotional well being. Interestingly, the sum of these components does not 
necessarily equal the subjective assessment of overall QoL 15. Although patients with 
malignant diseases may more often complain about physical problems such as pain and 
restriction in physical activities compared to healthy individuals, they may nevertheless 
report a relatively good overall QoL. For health professionals and bystanders, there seems 
to be a discrepancy between reported health-related problems and the patient’s personal 
judgment of overall health status.  
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A retrospective study evaluating postoperative QoL in patients undergoing LR for benign 
or malignant liver tumors was published previously. Interestingly, the study did not show 
a correlation between poor prognosis and postoperative QoL, a finding that may come as 
a surprise, considering the nature of certain illnesses 16. However, the retrospective 
design of the study and missing preoperative baseline QoL scores may have formed an 
impediment to correct interpretation of the data. Until now, no prospective studies have 
addressed the potential differences in long-term QoL in patients who have undergone LR 
for benign compared to malignant diseases 17. The aim of this study was to investigate 
the effect of LR on QoL in patients undergoing surgery for benign or malignant tumors.   
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Materials and Methods 
 
This prospective study included patients who underwent open or laparoscopic LR for 
benign or malignant tumors at the Department of Visceral Surgery and Medicine at the 
Inselspital, University Hospital in Bern, Switzerland between 06/2007 - 01/2013. Major LR 
was defined as removal of  ≥ 3 neighboring segments. Exclusion criteria were age under 
18 years, hepatobiliary surgeries only involving a liver biopsy, failure to perform a liver 
resection due to unexpected intraoperative findings or declined informed consent. All 
participants had a detailed preoperative briefing of the study and questionnaires involved.  
All participants in the study received the questionnaires preoperatively and after 1, 3, 6 
and 12 months post surgery. 
Quality of life was assessed using the European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30, version 3.0). This 
cancer-specific QoL instrument was originally used in clinical trials involving patients with 
cancer. It contains five functional scales, including physical, role, social, emotional, and 
cognitive functions, as well as questions specifically aimed at checking for symptoms often 
reported by cancer patients (fatigue, nausea/vomiting, pain, dyspnea, insomnia, loss of 
appetite, constipation/diarrhea). The financial impact that the disease has on the patient 
is also taken into account. The questionnaire consists of 30 items of which 28 have a 4-
point scale; 2 items have a 7-point scale for the overall QoL and health measure 18. In 
addition the QLQ-LMC21 was used. This questionnaire consists of 21 items, each of which 
has a 4-point scale. The QLQ-LMC21 was initially  designed to be used for patients with 
colorectal liver metastases because the general EORTC QLQ-C30 questionnaire did not 
adequately address problems specifically associated with hepatic metastases. Question 
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categories include items on food intake, weight loss, pain, jaundice, fatigue, social 
problems, anxiety, and the influence of the disease on sexual activity 19. 
 
Ethical considerations 
Ethical approval was obtained from the University of Bern ethical committee (institutional 
protocol number KEK 18/08). The study was also registered on ClinicalTrials.gov 
(NCT00681499). Written permission was obtained from all study participants. All eligible 
patients were given details of the study, including contact information of the researcher. 
Patients were informed about the aim of the study and were guaranteed anonymity and 
confidentiality with regard to the information given to the researcher. A licensing 
agreement was obtained from the EORTC for use of QLQ-C30, version 3.0 and the 
LMC21 questionnaires. 
 
Statistical analysis 
Primary and secondary outcomes based on multiply imputed data using repeated 
measures mixed-effects linear regression models adjusted for the baseline characteristics 
age, sex, jaundice, pruritus, weight loss, nausea, abdominal pain, lack of appetite, ASA 
Physical Status Classification System (used continuously), diabetes, cardiovascular 
disorders, pulmonary disorders and other disorders were analysed. The difference in 
scores between groups is presented with a corresponding 95% CI and p value.  
Missing score data were accounted for by multiple imputation assuming missing data to 
be missing at random. Each score (i.e., global health status, physical functioning, 
emotional functioning, fatigue and pain) was imputed separately by linear regression 
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methods based on the tumor type and the following variables: patient age at inclusion, 
hospital stay in days, ASA Physical Status Classification System (all used continuous), 
number of resected liver segments, death, relapse, sex, jaundice, pruritus, weight loss, 
nausea, abdominal pain, lack of appetite, diabetes, cardiovascular disorders, pulmonary 
disorders, other disorders, (neo)adjuvant chemotherapy, adjuvant radiotherapy, 
superficial infection, bilioma, pneumonia and other complications (all used categorical). In 
two cases, the number of segments and in four cases, hospital stay duration was missing. 
These were imputed along with global health status. Due to the absence of a monotone 
missing data pattern, we performed multiple imputation by chained equation was 
performed. In total, twenty imputed data sets were generated and analyzed as described 
above using Rubin’s rules (Rubin DB. Multiple Imputation for Nonresponse in Surveys. 
New York: J Wiley & Sons. 1987). Sensitivity analyses were based on complete data 
disregarding multiple imputation. All analyses were performed in STATA, release 13 
(Stata Inc, College Station, TX). 
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Results 
 
A total of 196 patients undergoing liver resection between 06/2007 – 01/2013 were initially 
included in the study. Eight patients were subsequently excluded due to unexpected, 
intraoperative findings resulting in no liver resection being performed. Thus 130 patients 
with malignant disease and 58 with a benign pathology were available for final analysis 
(Table 1 and Table 2). Patients with benign tumors were more often female (p=0.007) and 
younger (p=0.001) compared to patients with malignant tumors. Furthermore patients with 
benign disease presented more frequently with nausea (p=0.01), abdominal pain and a 
lower ASA score. Remaining baseline characteristics revealed no statistical differences 
between the groups (Table 1). 
The amount of liver tissue removed was not different between the groups, with 53% of 
patients with benign tumors requiring major liver surgery compared to 65% of patients with 
malignant tumors (p=0.223). Hospital length of stay was significantly longer in patients 
with malignant disease (p=0.001), (Table 3). 
The completeness of the EORTC questionnaires was analysed preoperatively and after 
1, 3, 6 and 12 months (data not shown). The completeness 12 months after surgery 
dropped from 98% preoperatively in both groups to 69% in patients with malignant disease 
and remained high at 97% in patients with benign disease. Drop out in the early stages 
was mainly due to patients not willing to take part anymore (because filling in the two 
questionnaires was “too tedious”). At later time points other factors, such as patient death 
or loss to follow-up, played a more important role. Eight (6%) patients with malignant 
tumors deceased within the 12 month follow-up period. No postoperative mortality 
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occurred in the benign disease group. In n=68 patients, recurrence of the underlying 
disease was noted.  
For the analysis of the QLQ-C30 and QLQ-LMC21 questionnaire, the individual 
parameters were summarized in the following 5 categories: global health status, physical 
functioning, emotional function, fatigue and pain.  
Global health status (as measured by the QLQ-C30 questionnaire) was equally low in 
patients with malignant and benign tumors in the preoperative setting and dropped 
similarly at one month after LR. Global health status improved over time in both groups, 
with the score gradually increasing again at 3, 6 and 12 months postoperatively. However, 
patients with benign disease showed a better global health status after 3, 6 and 12 months 
than to patients with malignant tumors (p<0.001, p=0.002, p=0.006). Also, in both patient 
groups, global health status was better 12 months after surgery  compared to preoperative 
values (p<0.001 benign, p=0.042 malignant). Patients with recurrent disease did not 
present with worse global health status (p=0.961) (Figure 1a). Similar results were found 
in the QLQ-C30 category physical functioning. Both patient groups recovered after an 
initial drop one month after surgery. Patients with benign disease presented with better 
physical functioning scores at 3, 6 and 12 months (p=0.011, p=0.025, p=0.041) compared 
to patients with malignant diseases (Figure 1b). Emotional function according to the QLQ-
C30 score was similar in both groups at baseline. Unlike the global health score and 
physical functioning score, there was no initial decrease in the emotional function score. 
The emotional functioning score continuously increased up to 12 months after LR, being 
identical in both groups at the 12-month time point. At 3 and 6 months, patients with benign 
disease presented with a slightly better emotional functioning score compared to patients 
with malignant disease (p=0.005, p=0.019) (Figure 1c). Fatigue as a symptom was 
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identical in both groups at baseline.  Fatigue scores increased to a similar extent one 
month after surgery in all patients and decreased to preoperative values in patients with 
malignant tumors. However, in patients with benign tumors fatigue was less pronounced 
at 3, 6 and 12 month compared to the patients with malignant disease (p=0.001, p=0.002, 
p=0.002) but also lower compared to baseline (Figure 1d). Mean scores for pain were 
identical in both groups at baseline, 1, 6 and 12 months. One month after LR, pain scores 
were still increased in all patients compared to preoperatively, with patients with malignant 
tumors having a significantly higher pain score, 3 months postoperatively compared to 
patients with LR for benign tumors (p=0.005), (Figure 1e).  
 
Discussion 
 
In this prospective study covering a longer time period quality of life in patients undergoing 
liver resection for benign or malignant tumors was evaluated. Liver resection was found 
to be safe and showed an acceptable morbidity and low mortality as previously reported 
1. As might be expected, self-reported overall quality of life, as measured by the global 
health status, showed a drop in the first month after surgery for both patient groups. It is 
essential that patients are informed preoperatively about this, reassuring them that QoL 
improves for the majority of patients after the first month. Already at the 3-month 
postoperative time-point, QoL increased substantially and continued to do so during the 
entire study period. For patients with benign pathologies, this finding is in line with the high 
percentage of symptom relief after liver resection previously demonstrated 20. Parallel to 
what can be observed in many specialized liver units worldwide 21, 22, minimally invasive 
 10 
liver resections are increasingly becoming gold standard in the present authors’ unit, 
making up the majority of hepatic resections in the currently. However, during the study 
period, patients still mainly underwent open hepatic surgery. Too low patient numbers 
concerning laparoscopic LR precluded statistical analyses, but the drop in self-reported 
QoL at one month postoperative may be expected to be less in patients undergoing 
laparoscopic resections 23.  
Some of the patients not answering the one month questionnaire were still in hospital at 
the given time point. It may seem fair to assume, that their self-reported overall QoL might 
be worse than the one actually reported. However, and surprisingly, patients suffering 
from postoperative complications who answered the questionnaires at the one month time 
period showed QoL scores that were not statistically different from those patients with an 
unproblematic postoperative course. This goes against what treating surgeons and 
physicians might expect. However, as has been shown by others 24, 25, self-reported QoL 
remains subjective, taking into account a multitude of equations. There are not solely 
based on measurable factors such as disease entity (malignant versus benign) or the 
presence or absence of physical restrictions and limitations.   
Interestingly, preoperative, that is “base-line” QoL was very similar in both patient groups, 
as were some of the main parameters analyzed by the QLQ-C30 and QLQ-LCM21 
(physical function, emotional functioning, fatigue and pain). This too seems contra-
intuitive, as one might expect patients with malignant diagnoses to fare worse. However, 
this may in part be explained by the fact that patients with benign tumors more frequently 
reported nausea and abdominal pain at the time point of their first consultation. It also may 
be explained by the patient’s general attitude and expectations towards the planned 
surgical intervention in case of a malignant diagnosis. Patients with a malignant tumor will 
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be aware of the fact, that surgery may be the only potentially long-term curative treatment 
strategy. Knowing that they qualify for surgery may thus result in an improved, self-
reported overall QoL. Similar findings have been reported by others 26.  
The findings of this study are limited by its single center design, restricting generalisation 
of the results. Also, patients with malignant diseases not responding to the survey may 
have had poor QoL, potentially adding a bias to the results presented. Finally, the sample 
size for this study was calculated for the overall, self-reported QoL but not for every sub-
analysis performed. 
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Figure Legends 
 
Table 1: Baseline characteristics of included patients (N=188) for each tumor type 
 
Table 2: Baseline table of tumor entities 
 
Table 3: Procedural characteristics and complications of included patients (N=188) for 
each tumor type 
 
Figure 1a-e: Scoring results of the QLQ-C30 and the QLQ-LMC21 
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Table 1: Baseline characteristics of included patients (N=188) for each tumor type  
All tumor groups Patients with 
malignant tumors 
Patients with 
benign tumors 
p value 
  (n=188) (n=130) (n=58)   Sex (female)    88 (47%)     52 (40%)    36  (62%)   0.007  Age  58.0 ± 13.4  61.7 ± 10.6  49.8 ± 15.2 <0.001  Jaundice                                         0.778   No   164 (87%)    114 (88%)    50  (86%)     Yes    24 (13%)     16 (12%)     8  (14%)    Pruritus                                         0.099   No   171 (91%)    115 (88%)    56  (97%)     Yes    17  (9%)     15 (12%)     2   (3%)    Weight loss                                         0.513   No   140 (74%)     95 (73%)    45  (78%)     Yes    48 (26%)     35 (27%)    13  (22%)    Nausea                                        <0.001   No   159 (85%)    118 (91%)    41  (71%)     Yes    29 (15%)     12  (9%)    17  (29%)    Abdominal pain                                        <0.001   No   128 (68%)    101 (78%)    27  (47%)     Yes    60 (32%)     29 (22%)    31  (53%)    Loss of appetite                                         0.096   No   147 (78%)    106 (82%)    41  (71%)     Yes    41 (22%)     24 (18%)    17  (29%)    ASA Physical Status Classification System                                         <0.001   Normal healthy patient    17  (9%)      6  (5%)    11  (19%)     Patients with mild systemic disease   101 (54%)     65 (50%)    36  (62%)     Patients with severe systemic disease    67 (36%)     57 (44%)    10  (17%)     Patients with severe systemic disease that is a constant threat to life     3  (2%)      2  (2%)     1   (2%)     Moribund patients who are not expected to survive without the operation     0  (0%)      0  (0%)     0   (0%)     A declared brain-dead patient whose organs are being removed for donor purposes     0  (0%)      0  (0%)     0   (0%)    Diabetes                                         0.820   No   163 (87%)    112 (86%)    51  (88%)     Yes    25 (13%)     18 (14%)     7  (12%)    Cardiovascular disorders                                         0.109   No   113 (60%)     73 (56%)    40  (69%)     Yes    75 (40%)     57 (44%)    18  (31%)    Pulmonary disorders                                         0.177   No   161 (86%)    108 (83%)    53  (91%)     Yes    27 (14%)     22 (17%)     5   (9%)    Kidney disease                                         0.440   No   181 (96%)    124 (95%)    57  (98%)     Yes     7  (4%)      6  (5%)     1   (2%)    Other disorders                                         0.266   No   108 (57%)     71 (55%)    37  (64%)     Yes    80 (43%)     59 (45%)    21  (36%)    
 18 
Data are n (%) or mean ± SD. P value: Fisher’s exact test or t-test as appropriate. * American Society of Anesthesiologists.   
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Table 2. Tumor types  All patients Malignant Benign           N = 196 N = 138 N = 58         Diagnosis n = 196,          n = 138,          n = 58,           Benign (excl. echinococcosis)          38 (19%)           0  (0%)         38 (66%)  Cholangiocarcinoma (incl. hilar cholangiocarcinoma)          17  (9%)          17 (12%)          0  (0%)  Colorectal liver metastases          57 (29%)          57 (41%)          0  (0%)  Echinococcosis          20 (10%)           0  (0%)         20 (34%)  Hepatocellular carcinoma          32 (16%)          32 (23%)          0  (0%)  Other liver metastases (excl. colorectal)          25 (13%)          25 (18%)          0  (0%)  Other primary malignant liver tumors           5  (3%)           5  (4%)          0  (0%)  Colorectal liver metastases & Hepatocellular carcinoma           2  (1%)           2  (1%)          0  (0%)                                  
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Table 3: Procedural characteristics and complications of included patients (N=188) for each tumor type 
 All tumor groups Patients with malignant tumor Patients with benign tumor p Value             N = 188 N = 130 N = 58             Number of resected liver segments                                        0.223   <3 segments (minor liver surgery)    71 (38%)     44 (34%)   27  (47%)    
 ≥3 segments (major liver surgery)   115 (61%)     84 (65%)   31  (53%)     Missing     2  (1%)      2  (2%)    0   (0%)    Hospital stay (days)  15.6 ± 13.0  18.1 ± 14.4  10.0 ± 6.4 <0.001  (Neo)adjuvant chemotherapy                                       <0.001   No   126 (67%)     69 (53%)   57  (98%)     Yes    62 (33%)     61 (47%)    1   (2%)          Adjuvant radiotherapy                                        0.010   No   175 (93%)    117 (90%)   58 (100%)     Yes    13  (7%)     13 (10%)    0   (0%)          Superficial infection                                        0.128   No   168 (89%)    113 (87%)   55  (95%)     Yes    20 (11%)     17 (13%)    3   (5%)          Deep infection                                        1.000   No   180 (96%)    124 (95%)   56  (97%)     Yes     8  (4%)      6  (5%)    2   (3%)          Bilioma                                        0.515   No   160 (85%)    109 (84%)   51  (88%)     Yes    28 (15%)     21 (16%)    7  (12%)          Hemorrhage/ hematoma                                        1.000   No   178 (95%)    123 (95%)   55  (95%)     Yes    10  (5%)      7  (5%)    3   (5%)          Thrombosis                                        0.523   No   186 (99%)    129 (99%)   57  (98%)     Yes     2  (1%)      1  (1%)    1   (2%)          Pulmonary embolism                                        1.000   No   186 (99%)    128 (98%)   58 (100%)     Yes     2  (1%)      2  (2%)    0   (0%)          Pneumonia                                        1.000   No   177 (94%)    122 (94%)   55  (95%)     Yes    11  (6%)      8  (6%)    3   (5%)          Other complications                                        0.001   No   139 (74%)     87 (67%)   52  (90%)    
 21 
 Yes    49 (26%)     43 (33%)    6  (10%)          Surgical reintervention                                        0.119   No   170 (90%)    114 (88%)   56  (97%)     Yes    17  (9%)     15 (12%)    2   (3%)     Missing     1  (1%)      1  (1%)    0   (0%)    Data are n (%) or mean ± SD. P value: Fisher’s exact test or t-test as appropriate.     
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Figure 1 a-f: Mean scores with 95% confidence intervals based on imputed data.   All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for the global health status / QoL represents a high QoL, a high score for a functional scale (e.g., physical functioning, emotional functioning) represents a high / healthy level of functioning, but a high score for a symptom scale / item (e.g., fatigue) represents a high level of symptomatology / problems.         
